Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 393 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Open-Angle Glaucoma Clear all
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Visior on Ocular Hemodynamics

NCT02959593
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
VISIOR video goggles
Device
Lead sponsor
Visior Technologies Ltd.
Industry
Eligibility
30 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 21, 2026, 7:26 PM EDT
Completed Phase 4 Interventional Results available

Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study

NCT03323164
View directory record Official record
Conditions
Glaucoma; Drugs, Normal Tension Glaucoma, Primary Open-angle Glaucoma
Interventions
Timolol Maleate, Brimonidine Tartrate
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 21, 2026, 7:26 PM EDT
Recruiting Phase 4 Interventional

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

NCT07217678
View directory record Official record
Conditions
Glaucoma, Open-Angle Glaucoma, Ocular Hypertension, Glaucoma Suspect
Interventions
Durysta, Bimatoprost Intracameral Implant 10 µg
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 21, 2026, 7:26 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)

NCT02167035
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Combigan Two Times Daily (BID), Simbrinza Three Times Daily (TID)
Drug
Lead sponsor
Cornerstone Health Care, PA
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 21, 2026, 7:26 PM EDT
Completed Phase 2 Interventional

Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

NCT01868126
View directory record Official record
Conditions
Open-angle Glaucoma or Ocular Hypertension
Interventions
DE-117 ophthalmic solution, latanoprost ophthalmic solution, Placebo
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
7
States / cities
Newport Beach, California • Morrow, Georgia • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Oct 21, 2026, 7:26 PM EDT
Completed Not applicable Interventional Results available

Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment

NCT03365778
View directory record Official record
Conditions
Primary Open-angle Glaucoma
Interventions
Patient Educational Intervention, Usual Care, Ophthalmologist Educational Intervention
Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 90 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 21, 2026, 7:26 PM EDT
Not listed No phase listed Observational

Efficacy and Safety Outcomes of Optometrist Performed Selective Laser Trabeculoplasty (SLT)

NCT04036214
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension
Interventions
Selective Laser Trabeculoplasty
Device
Lead sponsor
Northeastern State University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Tahlequah, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 21, 2026, 7:26 PM EDT
Completed Phase 4 Interventional

Assessing Cosopt Switch Patients

NCT00273442
View directory record Official record
Conditions
Ocular Hypertension, Open-Angle Glaucoma, Exfoliation Syndrome, Glaucoma, Pigmentary
Interventions
timolol maleate, dorzolamide/timolol maleate fixed combination
Drug
Lead sponsor
Pharmaceutical Research Network
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Bourbonnais, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2008 · Synced Oct 21, 2026, 7:26 PM EDT
Completed Phase 4 Interventional Results available

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

NCT03808688
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Netarsudil Ophthalmic Solution 0.02%
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
22
States / cities
Huntington Beach, California • Laguna Hills, California • Petaluma, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 21, 2026, 7:26 PM EDT
Not listed Not applicable Interventional

Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery

NCT01841450
View directory record Official record
Conditions
Primary Open Angle Glaucoma
Interventions
iStent, Cataract surgery
Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
22 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
14
States / cities
Irvine, California • Montebello, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 21, 2026, 7:26 PM EDT
Completed Phase 2 Interventional

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

NCT02312544
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
OTX-TP, Timolol
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 21, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension

NCT02250651
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Bimatoprost SR, Sham: Applicator Without Needle, Active Comparator: Timolol 0.5%, Timolol Vehicle (placebo)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
51
States / cities
Dothan, Alabama • Chandler, Arizona • Fayetteville, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 21, 2026, 7:26 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label Study of Safety of H1337 in Healthy Volunteers

NCT06572397
View directory record Official record
Conditions
Glaucoma Open-Angle Primary, Ocular Hypertension
Interventions
H-1337 1.0%
Drug
Lead sponsor
D. Western Therapeutics Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 21, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a Drug Delivery System in Glaucoma

NCT01016691
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 21, 2026, 7:26 PM EDT
Completed Phase 2 Interventional

Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

NCT02136940
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Eye Disease
Interventions
AMA0076, Placebo
Drug
Lead sponsor
Amakem, NV
Industry
Eligibility
30 Years to 85 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Artesia, California • Inglewood, California • Petaluma, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 21, 2026, 7:26 PM EDT
Not listed Phase 3 Interventional

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

NCT05165290
View directory record Official record
Conditions
Elevated Intraocular Pressure
Interventions
Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%
Drug
Lead sponsor
TearClear Corp
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Garden Grove, California • Glendale, California • Mission Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 21, 2026, 7:26 PM EDT
Terminated Phase 4 Interventional

A Clinical Study Comparing the Inflammatory Response of the Ex-Press Mini Shunt to Trabeculectomy

NCT00597181
View directory record Official record
Conditions
Glaucoma
Interventions
Trabeculectomy with mitomycin c, Ex-Press mini shunt with mitomycin c
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 17, 2010 · Synced Oct 21, 2026, 7:26 PM EDT
Withdrawn Not applicable Interventional

Effect of Negative Pressure on Pattern Electroretinography Readings

NCT04433702
View directory record Official record
Conditions
Glaucoma, Open Angle, Low Risk, Ocular Hypertension, Glaucoma Suspect
Interventions
Mercury™ Multi-Pressure Dial (MPD) Experimental Goggle, Mercury™ Multi-Pressure Dial (MPD) Placebo Goggle
Device
Lead sponsor
Vance Thompson Vision
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 21, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of SPARC0912 and Reference0912 in Open Angle Glaucoma or Ocular Hypertension

NCT00947661
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
SPARC0912, Reference0912
Drug
Lead sponsor
Sun Pharma Advanced Research Company Limited
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 21, 2026, 7:26 PM EDT
Completed Not applicable Interventional Results available

AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma

NCT02036541
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open Angle
Interventions
AqueSys XEN 45 Glaucoma Implant
Device
Lead sponsor
AqueSys, Inc.
Industry
Eligibility
45 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Glendale, Arizona • Fayetteville, Arkansas • Montebello, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 21, 2026, 7:26 PM EDT
Completed No phase listed Observational Results available

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

NCT00716742
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
1,099 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 6, 2012 · Synced Oct 21, 2026, 7:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dry Eye and Irritation Comparison of Latanoprost With the Preservative Versus Travoprost Without Preservative

NCT00803387
View directory record Official record
Conditions
Ocular Dryness, Ocular Irritation, Open-Angle Glaucoma, Ocular Hypertension
Interventions
Travaprost without BAC (Travatan Z)
Drug
Lead sponsor
United States Air Force
Federal
Eligibility
Not listed
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Lackland Air Force Base, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2008 · Synced Oct 21, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Results available

Travoprost Five Day Posology Study

NCT01114893
View directory record Official record
Conditions
Open-angle Glaucoma (OAG), Ocular Hypertension
Interventions
Travoprost 0.004%, Travoprost Vehicle, Travoprost (Groups A, B and C)
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2011 · Synced Oct 21, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Results available

Safety and Effects of Brimonidine Intravitreal Implant in Patients With Glaucomatous Optic Neuropathy

NCT00693485
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
400 ug Brimonidine Implant, 200 ug Brimonidine Implant, Sham (no implant)
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 21, 2026, 7:26 PM EDT